← All trials
NCT05591755
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 22, 2022
- Primary completion
- Jul 2, 2023
- Completion date
- Jul 2, 2023
- First posted
- Oct 24, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 224
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bausch & LombLead sponsor
- Bausch & LombStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.